+

WO1995032731A3 - Produits pharmaceutiques immunogenes - Google Patents

Produits pharmaceutiques immunogenes Download PDF

Info

Publication number
WO1995032731A3
WO1995032731A3 PCT/GB1995/001274 GB9501274W WO9532731A3 WO 1995032731 A3 WO1995032731 A3 WO 1995032731A3 GB 9501274 W GB9501274 W GB 9501274W WO 9532731 A3 WO9532731 A3 WO 9532731A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
pharmaceuticals
mutation
immunogenic
mutant protein
Prior art date
Application number
PCT/GB1995/001274
Other languages
English (en)
Other versions
WO1995032731A2 (fr
Inventor
Alain Robert Michael Townsend
Original Assignee
Univ Oxford
Medical Res Council
Alain Robert Michael Townsend
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford, Medical Res Council, Alain Robert Michael Townsend filed Critical Univ Oxford
Priority to AU26237/95A priority Critical patent/AU2623795A/en
Priority to JP8500539A priority patent/JPH10504702A/ja
Priority to EP95921028A priority patent/EP0762891A1/fr
Publication of WO1995032731A2 publication Critical patent/WO1995032731A2/fr
Publication of WO1995032731A3 publication Critical patent/WO1995032731A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

On décrit des produits pharmaceutiques qui comprennent tout ou partie d'une séquence polypeptidique ou nucléotidique codant pour tout ou partie d'un polypeptide, lequel est pour l'essentiel homologue d'une protéine mutante produite à la suite de sa mutation dans une séquence génique qui décale la traduction, à partir de la séquence génique de l'enzyme de lecture provenant d'une liste, vers la deuxième ou la troisième trame de lecture placée en aval de la mutation, tout ou partie de ce polypeptide pouvant provoquer une réponse immunitaire contre la protéine mutante.
PCT/GB1995/001274 1994-06-01 1995-06-01 Produits pharmaceutiques immunogenes WO1995032731A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU26237/95A AU2623795A (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals
JP8500539A JPH10504702A (ja) 1994-06-01 1995-06-01 免疫原製剤
EP95921028A EP0762891A1 (fr) 1994-06-01 1995-06-01 Produits pharmaceutiques immunogenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410922A GB9410922D0 (en) 1994-06-01 1994-06-01 Vaccines
GB9410922.0 1994-06-01

Publications (2)

Publication Number Publication Date
WO1995032731A2 WO1995032731A2 (fr) 1995-12-07
WO1995032731A3 true WO1995032731A3 (fr) 1995-12-21

Family

ID=10755982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001274 WO1995032731A2 (fr) 1994-06-01 1995-06-01 Produits pharmaceutiques immunogenes

Country Status (5)

Country Link
EP (1) EP0762891A1 (fr)
JP (1) JPH10504702A (fr)
AU (1) AU2623795A (fr)
GB (1) GB9410922D0 (fr)
WO (1) WO1995032731A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
JP2001522241A (ja) * 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ 診断方法および試薬
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
ITMI20030434A1 (it) 2003-03-07 2004-09-08 Istituto Oncologico Romagnolo Coope Rativa Sociale Metodo per l'individuazione di tumori del colon-retto.
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (fr) * 2006-02-27 2010-05-19 Univ Arizona Identification et utilisation de novopeptides pour le traitement du cancer
EP3075389A1 (fr) * 2015-03-31 2016-10-05 Technische Universität München Récepteurs de lymphocytes t et peptides dérivés par des mutations pour le traitement du cancer
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
GB201710812D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
WO2019055618A1 (fr) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Procédés de classification des réponses à une immunothérapie anticancéreuse
WO2020022898A2 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins standard contre le cancer
WO2020022899A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du sein
WO2020022903A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins à base de arid1a, cdkn2a, kmt2b, kmt2d, tp53 et pten contre le cancer
WO2020022900A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du rein
EP3827263A1 (fr) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Vaccins contre le cancer colorectal
WO2020022901A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer de l'utérus
EP4038222A4 (fr) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
EP0565794A1 (fr) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction des réponses CTL
WO1994010323A1 (fr) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus comprenant une fraction de liaison modifiee specifique contre des cellules cibles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
EP0565794A1 (fr) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction des réponses CTL
WO1994010323A1 (fr) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus comprenant une fraction de liaison modifiee specifique contre des cellules cibles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIRA HORII ET AL.: "The APC gene , responsible for familial adenomatous polyposis , is mutated in human gastric cancer", CANCER RESEARCH, vol. 52, pages 3231 - 3233 *
HARRIS C.C. ET AL.: "Clinical implications of the p53 tumor-suppressor gene", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 18 *
ROY N: "Generation of influenza-specific cytotoxic T-lymphocytes by retroviral gene transfer.", DISS ABSTR INT [B];54(3):1242 1993 *
YASUO MIYOSHI ET AL.: "Somatic mutations of the APC gene in colrectal tumors : mutation cluster region in the APC gene", HUMAN MOLECULAR GENETICS, vol. 1, no. 4, pages 229 - 233 *

Also Published As

Publication number Publication date
JPH10504702A (ja) 1998-05-12
EP0762891A1 (fr) 1997-03-19
WO1995032731A2 (fr) 1995-12-07
AU2623795A (en) 1995-12-21
GB9410922D0 (en) 1994-07-20

Similar Documents

Publication Publication Date Title
WO1995032731A3 (fr) Produits pharmaceutiques immunogenes
GR3022124T3 (en) A yeast cell of the genus schwanniomyces
WO1994026906A3 (fr) UN ADN CLONE CODANT UNE UDT-GALNAc:POLYPEPTIDE, N-ACETYLGALACTOSAMINYLTRANSFERASE
DE69529219D1 (en) Helicobacter proteine und impstoffe
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
CA2240334A1 (fr) Polymerase d&#39;adn thermostable issue de thermoanaerobacter thermohydrosulfuricus et enzymes mutants a activite d&#39;exonuclease supprimee ainsi obtenus
EP1688500A3 (fr) Surexpression de la Phytase dans la levure
CA2124214A1 (fr) Materiaux et methodes pour la biosynthese de la serine et de produits apparentes a la serine
WO1998021341A3 (fr) Procede de production par recombinaison de 1,3-propanediol
EP1522579A3 (fr) Gène de l&#39;hyaluronan synthase et son utilisation
AU4178800A (en) Hydantoinase variants with improved properties and their use for the production of amino acids
CA2252493A1 (fr) Gene de la .beta.-galactoside - .alpha. 2,6-sialyltransferase
WO1996034964A3 (fr) Polypeptide variant hk2 stable
AU8258591A (en) Human mk gene and protein sequence
DE69014046D1 (de) Verzweigungsenzym und dessen Verwendung.
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
HU9801384D0 (en) Clostridium perfringeus vaccine
EP0331356A3 (fr) Expression de protéines de fixant au VIH
AU3950799A (en) Genetically engineered yeast and mutants thereof for the efficient fermentation of lignocellulose hydrolysates
EP0736602A3 (fr) Sia-alpha-2,3-Gal-bêta-1,4 GlcNAc-alpha-2,8-sialyltransférase
WO1992013078A3 (fr) Gene pour la glycoprotease pasteurella haemolytica et son enzyme purifiee
Demoss et al. Characterization of subunit structural alterations which occur during purification of nitrate reductase from Escherichia coli
WO1995007357A3 (fr) Promoteurs
IE881016L (en) Stable creatine amidinohydrolase mutants
WO2001079489A3 (fr) 39228, nouvelle alcool-deshydrogenase et utilisations correspondantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995921028

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 750236

Date of ref document: 19970129

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995921028

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995921028

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载